Cytotoxic Effects of Vitamin D3 on Tumor Cell Lines




3(4,5-dimethyl- 2-thiazolyl)-2,5-diphenyl-2H-terazolium bromide, Tumor cell line, Vitamin D3, RD, L20B


Vitamin D3 is a potent antiproliferative agent against various tumor cells in vitro. Here, the results of Vitamin D3 study as a potential antitumor therapy in vitro are presented. Applying antiproliferative 3(4,5-dimethyl- 2-thiazolyl)-2,5-diphenyl-2H-terazolium bromide assays, the inhibitory effects of the Vitamin D were measured. The following cancer cell lines were employed: L20B (normal cell line) and RD (malignant rhabdomyosarcoma). Both cell lines were cultivated in 96-wells culture plates in the presence and absence of different doses of Vitamin D (10–6, 10–8, and 10–10 ?g/ml) for 24 and 48 h. In vitro results of cytotoxic effects were variable on both cell lines, according to dose and exposure time, after 24 h exposure of RD, the highest concentration of Vitamin D3(10?6 ?g/ml) treatment had significant effect in decreasing cell proliferation from O.D (0.4570 ± 0.0302) to (0.1540 ± 0.0017) as compared with negative control, with increasing concentrations the cytotoxicity is increased directly proportional; thus, the lowest cytotoxic effect was at the lowest concentration of both Vitamin D3 (10?12 ?g/ml). While after 48 h, the same concentration of Vitamin D3 shows an increase in proliferation from 0.3710 ± 0.0023 to 0.4597 ± 0.0017 on the RD cell line. While a significant increase in L20B cell proliferation was observed after 24 h treatment at the concentration (10?6 ?g/ml) from 0.3570 ± 0.0011 to 0.0330 ± 0.0017, when compared with the negative control. However, after 48 h treatment, a significant increases the proliferation of cells as shown from O.D 0.2927 ± 0.0008 to 0.4300 ± 0.0011, respectively. Thus, the present study was aimed to evaluate the antiproliferative property of Vitamin D and its relation to inhibition of cancer cell growth.


Download data is not yet available.


Al-Asady, A. A., K. H. H. Khalil and S. M. Barwari. 2012. Cytotoxic and cytogenetic effects of aqueous, methanolic and secondary metabolites extract of Capparis spinosa on tumor cell lines in vitro. Jordan J. Biol. Sci. 3(1): 15-30.

Bouillon, R., G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu and M. Demay. 2008. Vitamin D and human health: Lessons from Vitamin D receptor null mice. Endocr. Rev. 29: 726-776.

Colston, K., M. J. Colston and D. Feldman. 1981. 1, 25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology. 108: 1083- 1086.

Davis, J. S. and X. Wu. 2012. Current state and future challenges of chemoprevention. Discov. Med. 13: 385-390.

Diaz, G. D., C. Paraskeva, M. G. Thomas, L. Binderup and A. Hague. 2000. Apoptosis is induced by the active metabolite of Vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res. 60: 2304-2312.

Drag, M., P. Surowiak, M. Drag-Zalesinska, M. Dietel, H. Lage and J. Oleksyszyn. 2009. Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drugresistant cell lines. Molecules. 14(4): 1639-1651.

Fitzmaurice, C., C. Allen, R. M. Barber, L. Barregard, Z. A. Bhutta, H. Brenner H, D. J. Dicker, O. Chimed-Orchir, R. Dandona, L. Dandona, T. Fleming and M. H. Forouzanfar. 2017. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3(4): 524-548.

Gocek, E. and G. P. Studzinski. 2009. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 46: 190-209.

Hedlund, T. E., K. A. Moffatt and G. J. Miller. 1996. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25dihydroxyvitamin D3 in the human prostatic carcinoma cel line ALVA-31. J. Steroid Biochem. Mol. Biol. 58: 277-288.

Ko, P., R. Burkert, J. McGrath and D. Eyles. 2004. Maternal Vitamin D3 deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res. Dev. Brain Res. 153: 61-68.

Krishnan, A. V. and D. Feldman. 2010. Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer. 17: 19-38.

Lambert, J. R., J. A. Kelly, M. Shim, W. E. Huffer, S. K. Nordeen, S. J. Baek, T. E. Eling and M. S. Lucia. 2006. Prostate derived factor in human prostate cancer cells: Gene induction by Vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J. Cell. Physiol. 208: 566-574.

Lee, J. C., J. Kim, J. K. Park, G. H. Chung and Y. S. Jang. 2003. The antioxidant, rather than prooxidant, activities of quercetin on normal cells: Quercetin protects mouse thymocytes from glucose oxidasemediated apoptosis. Exp. Cell Res. 291(2): 386-397.

Lin, R., Y. Nagai, R. Sladek, Y. Bastien, J. Ho, K. Petrecca, G. Sotiropoulou, E. P. Diamandis, T. J. Hudson and J. H. White. 2002. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of Vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16: 1243-1256.

Palmer, H. G., M. Sánchez-Carbayo, P. Ordóñez-Morán, M. J. Larriba, C. Cordón-Cardó and A. Muñoz. 2003. Genetic signatures of differentiation induced by 1alpha, 25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63: 7799-7806.

Phelan, M. C. 1998. Basic techniques for mammalian to cell tissue culture. Curr. Protoc. Cell Biol. 7: 1-10.

Rani, D. and V. H. Somasundaram, S. 2012. Nair and M. Koyakutty. Advances in cancer nanomedicine. J. Indian Inst. Sci. 92: 187-218.

Samuel, S. and M. D. Sitrin. 2008. Vitamin D’s role in cell proliferation and differentiation. Nutr. Rev. 66: S116-S124.

Sylvester, P. W. 2011. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol. Biol. 716: 157-68.

Talib, H. W. 2011. Anticancer and antimicrobial potential of plantderived natural products. In: Rasooli, I. editor. Phytochemicals Bioactivities and Impact on Health. Ch. 6. University of Applied Science, Jordan. p388, 141-158.

Vanoirbeek, E., A. Krishnan, G. Eelen, L. Verlinden, R. Bouillon, D. Feldman and A. Verstuyf. 2011. The anti-cancer and antiinflammatory actions of 1, 25(OH)D. Best Pract. Res. Clin. Endocrinol. Metab. 25: 593-604.

Vuolo, L, C. Di Somma, A. Faggiano and A. Colao. 2012. Vitamin D and cancer. Front. Endocrinol. 3: 58.

Wang, T. T., F. P. Nestel, V. Bourdeau, Y. Nagai, Q. Wang, J. Liao, L. Tavera-Mendoza, R. Lin, J. W. Hanrahan, S. Mader and J. H. White. 2004. Cutting edge: 1, 25- dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173: 2909-2912.

Welsh, J. 2012. Cellular and molecular effects of Vitamin D on carcinogenesis. Arch. Biochem. Biophys. 523: 107-114.

Wu, W., X. Zhang and L. P. Zanello. 2007. 1α, 25-Dihydroxyvitamin D3 antiproliferative actions involve Vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21waf1 upregulation in human osteosarcoma. Cancer Lett. 254(1): 75-86.

Zamanian-Azodi, M., M. Rezaie-Tavirani, S. Heydari- Kashal, S. kalantari, S. Dalilan and H. Zali. 2012. Proteomics analysis of MKN45 cell line before and after treatment with Lavender aqueous extract. Gastroenterol. Hepatol. Bed Bench. 5: 35-42.



How to Cite

Mustafa, T. A., & Rasul, I. M. (2019). Cytotoxic Effects of Vitamin D3 on Tumor Cell Lines. Polytechnic Journal, 9(2), 100-104.



Research Articles